Form 4: Cartesian Therapeutics CFO Sells Shares to Cover Tax Obligations

Cartesian Therapeutics' Chief Financial Officer, Blaine Davis, sold a total of 7,989 shares of common stock to cover tax obligations and broker fees related to the vesting of restricted stock units.

Summary

• Blaine Davis, the Chief Financial Officer of Cartesian Therapeutics, sold shares of the company's common stock.
• The sales occurred on two separate dates: January 3, 2025, and January 6, 2025.
• On January 3, 2025, 3,961 shares were sold at a price of $16.7219 per share.
• On January 6, 2025, 4,028 shares were sold at a price of $16.8322 per share.
• The total number of shares sold was 7,989.
• These sales were made to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
• Following these transactions, Mr. Davis beneficially owns 94,811 shares of Cartesian Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for an executive to cover tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar sales by executives at other firms.
• The sale of 7,989 shares is not unusual for a CFO of a company of this size.

Stakeholder Impact

• The stock sales by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the routine nature of the transaction.

Key Dates

Keywords

Cartesian Therapeutics, Blaine Davis, stock sale, insider trading, Form 4, CFO, restricted stock units, tax obligations